Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[89Zr]DFO-starPEG PET Imaging in Solid Tumors
NCT06894745Phase 1Recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of [89Zr]DFO-starPEG in solid tumor (2 cohorts). Primary endpoints: Median Maximum Standardized Uptake Value up to 9 days, Tumor-to-background signal ratio (muscle) up to 9 days and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
[89Zr]DFO-starPEG
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06894745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06894745.